BCAX

11.83

10.78% -1.43

Handel nachbörslich: 11.83

Bicara Therapeutics Inc (BCAX)

Überblick Nachrichten Preisverlauf Forum Prognose

Schlusskurs vom Vortag:

$13.26

Offen:

$12.52

24-Stunden-Volumen:

662.79K

Relative Volume:

1.50

Marktkapitalisierung:

$645.01M

Einnahmen:

Nettoeinkommen (Verlust:

KGV:

EPS:

Netto-Cashflow:

1W Leistung:

-11.72%

1M Leistung:

-6.85%

6M Leistung:

-50.29%

1J Leistung:

+0.00%

1-Tages-Spanne:

$11.64

$12.80

1-Wochen-Bereich:

$11.64

$14.39

52-Wochen-Spanne:

$11.10

$28.09

Bicara Therapeutics Inc Stock (BCAX) Company Profile

Firmenname

Bicara Therapeutics Inc

Sektor

Healthcare (1174)

Branche

Biotechnology (678)

Telefon

617-785-8308

Adresse

245 MAIN STREET, CAMBRIDGE

Mitarbeiter

Twitter

Nächster Verdiensttermin

Neueste SEC-Einreichungen

BCAX's Discussions on Twitter

Vergleichen Sie BCAX mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
BCAX Bicara Therapeutics Inc	11.83	645.01M	0	0	0	0.00
VRTX Vertex Pharmaceuticals Inc	484.01	124.29B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.64	68.39B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	590.06	35.99B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	262.16	33.93B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	264.32	28.47B	3.81B	-644.79M	-669.77M	-6.24

Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-06	Eingeleitet	Wedbush	Outperform
2024-12-06	Eingeleitet	H.C. Wainwright	Buy
2024-11-05	Eingeleitet	Rodman & Renshaw	Buy
2024-10-08	Eingeleitet	Cantor Fitzgerald	Overweight
2024-10-08	Eingeleitet	Morgan Stanley	Overweight
2024-10-08	Eingeleitet	Stifel	Buy
2024-10-08	Eingeleitet	TD Cowen	Buy

Alle ansehen

Bicara Therapeutics Inc Aktie (BCAX) Neueste Nachrichten

01:36 AM

FY2025 EPS Estimates for BCAX Raised by Cantor Fitzgerald - Defense World

01:36 AM

Mar 31, 2025

Cantor Fitzgerald maintains Overweight on Bicara Therapeutics stock - Investing.com

Mar 31, 2025

Promising Data and Durable Responses Drive Buy Rating for Bicara Therapeutics - TipRanks

Mar 31, 2025

Q1 EPS Estimate for Bicara Therapeutics Reduced by Analyst - Defense World

Mar 31, 2025

Mar 29, 2025

Bicara Therapeutics (NASDAQ:BCAX) Earns Outperform Rating from Wedbush - Defense World

Mar 29, 2025

Mar 28, 2025

Charles Schwab Investment Management Inc. Takes Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 28, 2025

Stifel raises Bicara stock price target to $48, maintains Buy By Investing.com - Investing.com Canada

Mar 28, 2025

Buy Rating for Bicara Therapeutics Inc. Driven by Promising Clinical Progress and Strong Financial Position - TipRanks

Mar 28, 2025

Bicara Therapeutics Reports Strong Financial Position and Clinical Progress - TipRanks

Mar 28, 2025

Mar 27, 2025

Analysts Adjust Price Targets For Nkarta And Bicara - Evrim Ağacı

Mar 27, 2025

Stifel raises Bicara stock price target to $48, maintains Buy - Investing.com India

Mar 27, 2025

Bank of New York Mellon Corp Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX) - Defense World

Mar 27, 2025

Bicara Therapeutics Inc QTRLY Loss Per Share $0.39 - MarketScreener

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - GlobeNewswire

Mar 27, 2025

Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ... - Enid News & Eagle

Mar 27, 2025

Mar 26, 2025

Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025 - GlobeNewswire

Mar 26, 2025

Mar 18, 2025

Skandinaviska Enskilda Banken AB publ Purchases Shares of 38,035 Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat

Mar 18, 2025

Mar 15, 2025